Yuhan Corporation
000100
Rangering i aksjer
#3832
Yuhan Corporation, a prominent South Korean pharmaceutical firm established in... Yuhan Corporation, a prominent South Korean pharmaceutical firm established in 1926 and headquartered in Seoul, specializes in the research, development, and manufacture of active pharmaceutical ingredients (APIs) and intermediates for both domestic and international markets. Its extensive product portfolio encompasses a wide array of prescription pharmaceuticals (ETC), addressing therapeutic areas such as cardiovascular, alimentary, genito-urinary, metabolic, respiratory, allergy, and neurological systems, alongside anti-infectives, anti-cancer treatments, and hormonal therapies. Notable offerings include Revanex, an acid pump antagonist designed for treating peptic ulcers and gastritis-related mucosal injury. Beyond prescription drugs, Yuhan Corporation provides a diverse range of over-the-counter (OTC) medications, including vitamins, mineral supplements, hepatopathy treatments, tonics, and drugs for respiratory, alimentary, dermatological, and pain relief applications. The company also extends its reach into consumer health and household goods, producing items like bleaches, detergents, pesticides, and oral care products. Further diversifying its operations, Yuhan is involved in the dental sector, supplying implants, equipment, consumables, and dental care solutions, and manufactures veterinary medical supplies for livestock, aquatic species, and companion animals. Additionally, it offers contract manufacturing services to other businesses.
Aksjekurs
$63.22
Markedsverdi
$4.27B
Endring (1 dag)
-3.12%
Endring (1 år)
-23.57%
Land
KR
Handel Yuhan Corporation (000100)
Kategori
Healthcare
Inntekter for Yuhan Corporation (000100)
Inntekter i Jun 2026 TTM: $1.72B
Ifølge de nyeste økonomiske rapportene til Yuhan Corporation er selskapets nåværende inntekter (TTM) $1.72B. I 2024 hadde selskapet inntekter på $1.41B en nedgang sammenlignet med inntektene i 2023, som var $1.44B. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Yuhan Corporation fra 2007 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $1.72B | 13.61% |
| 2025 | $1.51B | 7.62% |
| 2024 | $1.41B | -2.06% |
| 2023 | $1.44B | 2.04% |
| 2022 | $1.41B | -0.87% |
| 2021 | $1.42B | -4.85% |
| 2020 | $1.49B | 16.39% |
| 2019 | $1.28B | -6.01% |
| 2018 | $1.36B | -0.59% |
| 2017 | $1.37B | 25.25% |
| 2016 | $1.10B | 14.05% |
| 2015 | $960.45M | 3.29% |
| 2014 | $929.82M | 3.74% |
| 2013 | $896.29M | 22.88% |
| 2012 | $729.40M | 24.46% |
| 2011 | $586.04M | -0.96% |
| 2010 | $591.75M | 6.18% |
| 2009 | $557.33M | 17.68% |
| 2008 | $473.59M | -10.14% |
| 2007 | $527.01M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $23.54B | 1,268.60% |
DE
|
|
| $23.73B | 1,280.21% |
DE
|
|
| $29.24B | 1,600.31% |
JP
|
|
| $5.85B | 240.11% |
CH
|
|
| $6.34B | 268.81% |
IN
|
